Proposed Change:
The Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the Office of the Director, National Institutes of Health (NIH) is seeking public comment regarding its proposal to establish the following offices within DPCPSI: Office of Research Innovation, Validation, and Application (ORIVA) and Office of Research Economics, Planning, and Analysis (OREPA). The program offices in DPCPSI share a common mission of identifying emerging scientific opportunities, rising public health challenges, or scientific knowledge gaps that deserve special emphasis.
Office of Research Innovation, Validation, and Application (ORIVA)
This proposed office will strengthen integration with NIH-wide initiatives related to scientific innovation, alternative test methods, reproducible research, and regulatory translation; and reaffirm NIH’s commitment to advancing scientifically valid alternatives to animal testing. ORIVA will be composed of two divisions: Division for Accelerating Innovation in Biomedical Research (DAIBR) and the Division of the National Interagency Center for the Evaluation of Alternative Test Methods (DNICEATM).
Office of Research Economics, Planning, and Analysis (OREPA)
This proposed office will play a central role in planning, coordinating, and reporting on NIH-wide initiatives and their impact, including health research economics and replication and reproducibility, analyzing the research portfolio, aligning strategic priorities, and ensuring the effective use of NIH resources. OREPA will be composed of three offices: Office of Planning, Performance, Evaluation, and Reporting (OPPER); Office of Portfolio Analysis (OPA); and the Office of Replication and Reproducibility (ORR). OPPER, formerly known as the Office of Evaluation, Performance, and Reporting, and OPA are already established within DPCPSI and will be transferred under OREPA.
Questions and Comments
Please submit questions/comments by email to [email protected] by 11:59pm ET on Monday, January 26, 2026.

